"Walgreen (WAG) a holding on our recommended buy list, reported a 10% increase in its fiscal second-quarter profit," notes Geoffrey Seiler.

The editor of BullMarket.com explains, "Although investors hammered the stock, we think the company delivered solid sales growth. We continue to believe the best is yet to come for Walgreen, with several notable catalysts in the wings.

Continue reading Walgreen: Overreaction Creates Opportunity

Walgreen: Overreaction Creates Opportunity originally appeared on BloggingStocks on Mon, 28 Mar 2011 13:00:00 EST. Please see our terms for use of feeds.

"According to the Spectrem Group, which recently polled the country's wealthiest people, they're the most optimistic they've been in months," says Marc Lichtenfeld.

The contributing editor to Investment U explains, "Let's take a look at 3 stocks that millionaires (and aspiring ones) should pay attention to: Apple (AAPL), Bristol-Myers Squibb (BMY) and Varian Medical Systems (VAR).

"And according to Fidelity, 83% of millionaires surveyed said the financial crisis did not shake their confidence in investing. And of those who said they'll invest more money in the stock market, nearly 60% of them plan to buy technology stocks. And just under half expect to acquire pharmaceutical and healthcare stocks.

Continue reading Three Favorite Stocks of Wealthy Investors

Three Favorite Stocks of Wealthy Investors originally appeared on BloggingStocks on Wed, 23 Mar 2011 15:30:00 EST. Please see our terms for use of feeds.

"We follow an approach to investng that focuses on broadly diversified investments in undervalued stocks for their long-term appreciation potential," says value investor John Buckingham.

The money manager and editor of The Prudent Speculator explains, " Two recently featured ideas -- Abbott Laboratories (ABT) and Baxter International (BAX) -- are among those we feel could serve as a portfolio foundation or as a new ideas for well- diversified holdings.

Continue reading Abbott (ABT) and Baxter (BAX): Healthy Gains

Abbott (ABT) and Baxter (BAX): Healthy Gains originally appeared on BloggingStocks on Tue, 01 Mar 2011 10:00:00 EST. Please see our terms for use of feeds.

"Novo Nordisk A/S (NVO) is a Danish pharmaceutical company that focuses on diabetes care and biopharmaceuticals," notes Nicholas Vardy.

The editor of the Global Bull Market Alert explains, "Novo Nordisk is a quiet giant, employing 30,000 people in 76 countries; we think investors could double their money with this profit machine.

"More than 200 million people worldwide suffer from some form of diabetes. Patients with type 1 (juvenile) diabetes can't make insulin at all and need to inject it their whole lives.

Continue reading Novo Nordisk A/S (NVO): Health Care 'Profit Machine'

Novo Nordisk A/S (NVO): Health Care 'Profit Machine' originally appeared on BloggingStocks on Wed, 23 Feb 2011 13:00:00 EST. Please see our terms for use of feeds.

"Accretive Health (AH) has been a solid performer in our Fast-Track Portfolio, jumping from $13 to nearly $20 in six months," notes Andy Obermueller.

The editor of Fast-Track Millionaire -- who focuses on long-term growth stocks -- explains, "I admit, the company is not very sexy -- helping hospitals maximize their revenue cycle. But what I've been looking at with the company is very alluring indeed.

Continue reading Accretive Health (AH): Hospital Returns

Accretive Health (AH): Hospital Returns originally appeared on BloggingStocks on Tue, 22 Feb 2011 11:00:00 EST. Please see our terms for use of feeds.

"We own a healthy dose of Fidelity Select Healthcare (FSPHX) in each of our model portfolios," says fund expert Jim Lowell.

The editor of Fidelity Investor explains, "Manager Eddie Yoon and I caught up this month. His command of the sector and his growth-oriented discipline continue to serve us well on both our risk-adjusted and real return fronts/

"Of course, healthcare (representing nearly 16% of our total GDP) is unlike any other sector in the S&P. It is so diversified and global, so interrelated to technology, manufacturing, and R&D, so dependent upon delivering real goods and services for consumer consumption, that it is almost an economy unto itself.

Continue reading Fidelity Select Healthcare (FSPHX): The Right Prescription

Fidelity Select Healthcare (FSPHX): The Right Prescription originally appeared on BloggingStocks on Thu, 17 Feb 2011 13:00:00 EST. Please see our terms for use of feeds.

"The visible growth story at Jazz Pharmaceuticals (JAZZ) is the narcolepsy treatment Xyrem, which accounts for 85% of revenues," says growth stock specialist Mike Cintolo.

The editor of Cabot Top Ten Weekly Report explains, "But Jazz has great potential to make big money with other drugs too-all of which focus on the chemistry of the brain.

"Thanks to patents, Jazz has a decade to run with Xyrem before generic competitors can enter the market. Meanwhile, its drugs have potential to treat and/or cure obsessive-compulsive disorders, anxiety disorders, fibromyalgia, epilepsy and restless leg syndrome.

Continue reading All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety

All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety originally appeared on BloggingStocks on Tue, 08 Feb 2011 11:00:00 EST. Please see our terms for use of feeds.

This post is one in a series in which more than 60 newsletter advisors share their Top Stock Picks for 2011. This special report is courtesy of TheStockAdvisors.com.

"For over 50 years, Medtronic (MDT) has been the premier medical device manufacturer in the marketplace," notes Jim Stack.

The money manager and editor of InvesTech Market Analyst explains, "With the invention of the battery-powered pacemaker in the mid 1950s, Medtronic began a long string of technological innovations.

Continue reading Top Picks 2011: Medtronic (MDT)

Top Picks 2011: Medtronic (MDT) originally appeared on BloggingStocks on Tue, 04 Jan 2011 13:00:00 EST. Please see our terms for use of feeds.

"After releasing their 3Q financials. the stock price at Isis Pharmacueticals (ISIS) perked up as their large cash position and deep pipeline have attracted some new investors," notes biotech expert John McCamant.

The editor of The Medical Technology Stock Letter explains, "When investors investigate the ISIS story and all its parts, they come away with an appreciation for all the potential long-term value being created at the company.

Continue reading Isis (ISIS): 'Deep Pipeline, Long-Term Value'

Isis (ISIS): 'Deep Pipeline, Long-Term Value' originally appeared on BloggingStocks on Fri, 17 Dec 2010 13:00:00 EST. Please see our terms for use of feeds.

Continue reading Express Scripts (ESRX): The Right Prescription?

Express Scripts (ESRX): The Right Prescription? originally appeared on BloggingStocks on Tue, 07 Dec 2010 10:50:00 EST. Please see our terms for use of feeds.

The editor of Dow Theory Forecasts explains, "One exception is Abbott Laboratories (ABT); Wall Street expects to increase earnings at a 10% annual rate over the next five years.

"Yet the market appears to discount that outlook, and the stock's price/earnings-to-growth ratio (PEG) of 1.2 is well below its peers.

Continue reading Abbott Labs (ABT): A Rich Pipeline in Pharma

Abbott Labs (ABT): A Rich Pipeline in Pharma originally appeared on BloggingStocks on Wed, 01 Dec 2010 10:20:00 EST. Please see our terms for use of feeds.

"I love going to health care conferences, where companies often reveal new technologies, groundbreaking drugs, or novel ways of attacking diseases," says Marc Lichtenfeld.

The contributing editor to Investment U explains, "Here's a review of four interesting presentations I recently saw at LifeTech Capital's small-cap health care conference in Miami: Inovio Pharmaceuticals (INO), Nabi Pharmaceuticals (NABI), NeoStem (NBS), and Oculus Innovative Sciences (OCLS).

Continue reading Health Care Conference Highlights Speculative Innovators

Health Care Conference Highlights Speculative Innovators originally appeared on BloggingStocks on Tue, 23 Nov 2010 13:00:00 EST. Please see our terms for use of feeds.

"Myriad Genetics (MYGN) is an innovative company that can diagnose your risk of cancer years before you have any symptoms," notes growth stock expert Lou Basenese.

The editor of White Cap Research explains, "Even better, it benefits from no competition and one of the best research and development teams around.

"Myriad Genetics' main product is called BRACAnalysis, which is a test that analyzes a woman's genetics to determine her likelihood of developing breast and ovarian cancers. Plain and simple, the test saves lives ... and money.

Continue reading Myriad Genetics (MYGN): Speculating on Cancer Diagnosis

Myriad Genetics (MYGN): Speculating on Cancer Diagnosis originally appeared on BloggingStocks on Fri, 19 Nov 2010 13:00:00 EST. Please see our terms for use of feeds.

Cardinal Health's shares (CAH), first discussed here on April 27, 2009, at a pre-spin-off price of $34.22, continued to meander over the past four months, but I still like the business model at this juncture. Here's why.

Cardinal probably will post a 3% to 5% 2010 revenue rise, followed by a 2% to 4% increase in 2011.

Key operation factors working in CAH's favor include increased prescription sales, modest pricing power, better performance of wider-margin generic drugs, lower customer attrition, and more-effective cost controls. Cardinal's medical unit, however, will lag other divisions, due to soft hospital markets.

Continue reading Cardinal Health Is Trying Investors' Patience

Cardinal Health Is Trying Investors' Patience originally appeared on BloggingStocks on Wed, 17 Nov 2010 17:30:00 EST. Please see our terms for use of feeds.

The editor of Validea continues, "Sanofi-Aventis (SNY), which is involved in pharmaceuticals and human vaccines, earns a Guru Score of 100% based on the value investing strategy of Benjamin Graham.

"In its pharmaceutical activity, the company specializes in six therapeutic areas: diabetes, oncology, thrombosis and cardiovascular, central nervous system (CNS), and internal medicine.

Continue reading Sanofi-Aventis (SNY): A Ben Graham Value Buy

Sanofi-Aventis (SNY): A Ben Graham Value Buy originally appeared on BloggingStocks on Mon, 25 Oct 2010 11:00:00 EST. Please see our terms for use of feeds.

"Foreign corporations have been on a mini buying spree in 2010. Not surprising, merger and acquisition activity has heated up a bit in the drug sector," says Chuck Carlson, editor of The DRIP Investor.

The dividend expert explains, " Global merger and acquisition activity topped $1 trillion in the first half of 2010, a 9.4% increase over the previous year. And Bristol-Myers Squibb (BMY), recommend stock in our Editor's Portfolio, has been one of the more active participants.

Continue reading Bristol-Myers Squibb (BMY): Buying Growth?

Bristol-Myers Squibb (BMY): Buying Growth? originally appeared on BloggingStocks on Wed, 29 Sep 2010 13:00:00 EST. Please see our terms for use of feeds.

"Two of our long-standing buy recommendations are involved in selling products and services for the genetic research market: Affymetrix (AFFX) and Illumina (ILMN)," notes biotech and growth stock specialist Nate Pile.

The editor of Nate's Notes explains, "In a nutshell, both of these companies have developed technologies that allow researchers to do what is known as 'high-throughput genetic screening'.

"And, while the two companies are direct competitors in many of the markets in which they compete, we believe that both stocks should be bought at the current time.

Continue reading Genetic Gains? Affymetrix (AFFX) and Illumina (ILMN)

Genetic Gains? Affymetrix (AFFX) and Illumina (ILMN) originally appeared on BloggingStocks on Tue, 21 Sep 2010 10:20:00 EST. Please see our terms for use of feeds.

"President Obama's push into digital medical records could lead to a profit surge for Quality Systems (QSII)," says Andy Obermueller, an adviser who specializes in analyzing the investment opportunities related to new government programs and legislation.

The editor of Government-Driven Investing explains, "Better access to records will show doctors a more complete view of their patients, reduce error and prevent redundant tests.

"In my view, it is not a question of if medical service providers are going to buy these system, it's a question of when. And the cost savings of digital medical records could be significant.

Continue reading Digital Medical Records Boost Quality Systems (QSII)

Digital Medical Records Boost Quality Systems (QSII) originally appeared on BloggingStocks on Fri, 17 Sep 2010 13:00:00 EST. Please see our terms for use of feeds.

"For years the health care sector had a well-deserved reputation for consistent returns and profitability regardless of broader economic conditions," observes Elliott Gue.

The contributing editor to Personal Finance explains, "But the past two years have challenged this reputation, and these stocks are out of favor. Some favorites, such as Novartis (NVS) are trading at their most attractive valuation in years.

"Although the sector faces undeniable challenges, markets often overreact to new regulation, providing attractive entry points for savvy investors and a low bar of expectations.

Continue reading Novartis (NVS): Pharma Favorite with Solid Pipeline

Novartis (NVS): Pharma Favorite with Solid Pipeline originally appeared on BloggingStocks on Thu, 26 Aug 2010 13:00:00 EST. Please see our terms for use of feeds.

"Pharmacy benefits managers (PBMs) are the main distributors of drugs to retail pharmacies and directly to consumers; in our view, the PBM sector is a must-have health care area for investors," says Stephen Leeb.

The editor of The Complete Investor explains, "Express Scripts (ESRX) is a leading and fast-growing pure-play PBM that has been generating impressive results and is undervalued relative to the industry.

"One striking health care trend in recent years has been a dramatic rise in prescriptions. For the 10 years ended in 2009, according to a government study, the number of prescription drugs dispensed in the U.S. rose 39 percent, while U.S. population growth was just 9 percent.

Continue reading Express Scripts (ESRX): Prescription for Profits

Express Scripts (ESRX): Prescription for Profits originally appeared on BloggingStocks on Mon, 09 Aug 2010 10:00:00 EST. Please see our terms for use of feeds.